Literature DB >> 7273601

Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate.

M C Nahata, D A Powell.   

Abstract

Bioavailability of chloramphenicol and kinetics of chloramphenicol succinate and chloramphenicol were studied in 12 patients. Chloramphenicol succinate, 25 mg/kg, was injected intravenously every 6 hr over 0.5 to 1 hr. Both the drug and the prodrug were analyzed by high-pressure liquid chromatography. Bioabailability of chlorampenicol ranged from 0.55 to 0.92 and total, renal, and nonrenal clearance from 6.81 to 98.22, 2.54 to 26.90, and 3.73 to 87.38 ml/m2/min, while clearances of chloramphenicol succinate ranged from 84.75 to 916.00 28.40 to 312.00, and 26.06 to 760.93 ml/m2/min. Urinary recovery of chloramphenicol was 3% to 25% and that of chloramphenicol succinate was 7% to 45%. Mean apparent volumes of distribution were 0.71 l/kg for chloramphenicol and 2.10 l/kg for chloramphenicol succinate and elimination half-lifes were 4.03 and 2.65 hr, respecitively. There were relationships between patient age and clearance of both drugs. Incomplete bioavailability of chloramphenicol and the more than 10-fold variability in clearance of both chloramphenicol and chloramphenicol succinate explain the need for individualizing doses to achieve thrapeutic effect and minimize the risk to toxicity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273601     DOI: 10.1038/clpt.1981.174

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Interplay between pediatric pharmacy practice and research to influence patient care.

Authors:  Milap C Nahata
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

Review 2.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 3.  Prodrugs.

Authors:  D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Ensuring safe and effective medication use in pediatric patients.

Authors:  Milap C Nahata
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

Review 5.  Prodrugs. Do they have advantages in clinical practice?

Authors:  V J Stella; W N Charman; V H Naringrekar
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate.

Authors:  P J Ambrose
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

7.  Pharmacokinetics of cefuroxime axetil suspension in infants and children.

Authors:  D A Powell; N C James; M J Ossi; M C Nahata; K H Donn
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 8.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

9.  Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.

Authors:  Iftekhar Mahmood
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-02-12       Impact factor: 2.441

Review 10.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.